Corbus Pharmaceuticals Holdings Inc.

NAS: CRBP

GO
/marketstate/country/us

Countdown to close

 --Real time quotes

Aug 11, 2020, 3:38 p.m.

/zigman2/quotes/201549545/composite

$

6.98

Change

+0.11 +1.53%

Volume

Volume 2.14m

Real time quotes

/zigman2/quotes/201549545/composite

Previous close

$ 6.87

$ 6.98

Change

+0.11 +1.53%

Day low

Day high

$6.72

$7.53

Open

52 week low

52 week high

$3.29

$8.78

Open

Company Description

Corbus Pharmaceuticals Holdings, Inc. is a phase 3 clinical-stage pharmaceutical company, which focuses on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company's lead product candidate, lenabasum, is a novel, ...

Corbus Pharmaceuticals Holdings, Inc. is a phase 3 clinical-stage pharmaceutical company, which focuses on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus. The company was founded on December 18, 2013 and is headquartered in Norwood, MA.

Valuation

Price to Sales Ratio

9.65

Price to Book Ratio

57.35

Enterprise Value to Sales

9.04

Total Debt to Enterprise Value

0.03

Efficiency

Revenue/Employee

256,337.00

Income Per Employee

-506,764.00

Receivables Turnover

26.96

Total Asset Turnover

0.75

Liquidity

Current Ratio

1.09

Quick Ratio

1.09

Cash Ratio

0.91

Profitability

Operating Margin

-226.01

Pretax Margin

-210.37

Net Margin

-197.69

Return on Assets

-148.66

Return on Equity

-424.29

Return on Total Capital

-375.38

Return on Invested Capital

-342.06

Capital Structure

Total Debt to Total Equity

153.40

Total Debt to Total Capital

60.54

Total Debt to Total Assets

19.22

Long-Term Debt to Equity

131.50

Long-Term Debt to Total Capital

51.89

Officers and Executives

Name Age Officer Since Title
Dr. Yuval Cohen 44 2013 Chief Executive Officer & Director
Dr. Robert Discordia 55 2018 Chief Operating Officer
Mr. Sean F. Moran 61 2014 Chief Financial & Accounting Officer
Dr. Barbara White 68 2014 Chief Medical Officer
Dr. Sergei Atamas - 2019 Executive Director-Research

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
03/17/2020 Barbara White
Chief Medical Officer
15,606   Acquisition at $3.63 per share. 56,649
03/17/2020 Yuval Cohen
Chief Executive Officer; Director
4,300   Acquisition at $3.49 per share. 15,007
03/17/2020 Robert Discordia
Chief Operating Officer
2,840   Acquisition at $3.54 per share. 10,053
03/17/2020 Craig Millian
Chief Commercial Officer
2,000   Acquisition at $4.25 per share. 8,500
11/12/2019 Barbara White
Chief Medical Officer
3,424   Acquisition at $4.38 per share. 14,997
11/12/2019 Yuval Cohen
Chief Executive Officer; Director
1,430   Acquisition at $4.26 per share. 6,091
11/11/2019 Robert Discordia
Chief Operating Officer
2,500   Acquisition at $4.62 per share. 11,550
11/11/2019 Craig Millian
Chief Commercial Officer
1,000   Acquisition at $4.38 per share. 4,380
08/15/2019 Craig Millian
Chief Commercial Officer
1,500   Acquisition at $5.48 per share. 8,220
08/12/2019 Barbara White
Chief Medical Officer
1,639   Acquisition at $6.1 per share. 9,997
08/12/2019 Yuval Cohen
Chief Executive Officer; Director
1,175   Acquisition at $6.06 per share. 7,120
08/12/2019 Robert Discordia
Chief Operating Officer
15,000   Acquisition at $5.86 per share. 87,900
08/12/2019 Craig Millian
Chief Commercial Officer
1,500   Acquisition at $6 per share. 9,000
05/17/2019 Barbara White
Chief Medical Officer
1,389   Acquisition at $7.2 per share. 10,000
05/14/2019 Sean F. Moran
Chief Financial Officer
100   Acquisition at $7.12 per share. 712
05/14/2019 Craig Millian
Chief Commercial Officer
1,000   Acquisition at $7.23 per share. 7,230
05/13/2019 Yuval Cohen
Chief Executive Officer; Director
995   Acquisition at $6.99 per share. 6,955
03/15/2019 David P. Hochman
Director
2,000   Acquisition at $6.98 per share. 13,960
03/15/2019 John Kenneth Jenkins
Director
1,000   Acquisition at $6.98 per share. 6,980
03/14/2019 Sean F. Moran
Chief Financial Officer
1,500   Acquisition at $6.67 per share. 10,005
03/14/2019 Barbara White
Chief Medical Officer
4,638   Acquisition at $6.47 per share. 30,007
03/14/2019 Yuval Cohen
Chief Executive Officer; Director
1,530   Acquisition at $6.49 per share. 9,929
03/14/2019 Craig Millian
Chief Commercial Officer
5,000   Acquisition at $6.85 per share. 34,250
/news/latest/company/us/crbp

MarketWatch News on CRBP

  1. Corbus Pharmaceuticals stock price target raised to $32 from $12 at Instinet

    10:18 a.m. June 4, 2020

    - Tomi Kilgore

  2. Coronavirus Is Bad — and Good — for Biotech Stocks

    5:52 p.m. March 10, 2020

    - Barron's Online

  3. Money flows in marijuana stocks are mostly negative

    11:26 a.m. Aug. 20, 2019

    - Nigam Arora

  4. The one must-know thing that could help marijuana investors

    12:20 p.m. June 3, 2019

    - Nigam Arora

  5. Corbus Pharmaceuticals started at outperform with $28 stock price target at Oppenheimer

    7:24 a.m. March 19, 2019

    - Tomi Kilgore

  6. These three marijuana stocks are rising in popularity

    10:29 a.m. Feb. 22, 2019

    - Nigam Arora

  7. How to tell when a marijuana-stock rally is real or a mirage

    12:17 p.m. Feb. 11, 2019

    - Nigam Arora

  8. Dow Falls 350 Points Because Doubt Springs Eternal

    4:32 p.m. Dec. 7, 2018

    - Barron's Online

  9. Corbus Pharmaceuticals started at buy with $22 stock price target at B. Riley FBR

    11:54 a.m. Oct. 24, 2018

    - Tomi Kilgore

  10. S&P 500 is displaying some worrisome moves, as bulls hold on

    1:29 p.m. Oct. 4, 2018

    - Lawrence G. McMillan

  11. Corbus Pharmaceuticals started at outperform with $24 stock price target at Raymond James

    9:05 a.m. Jan. 19, 2018

    - Tomi Kilgore

  12. Harry Boxer’s four stocks popping to start the new year

    2:20 p.m. Jan. 3, 2018

    - Harry Boxer

  13. Loading more headlines...
/news/nonmarketwatch/company/us/crbp

Other News on CRBP

  1. 10-Q: CORBUS PHARMACEUTICALS HOLDINGS, INC.

    5:30 p.m. Aug. 6, 2020

    - Edgar Online - (EDG = 10Q, 10K)

  2. Corbus Pharmaceuticals secures debt funding of $50M

    9:15 a.m. July 29, 2020

    - Seeking Alpha

  3. Corbus nearing finish line in lenabasum study in cystic fibrosis

    10:12 a.m. June 22, 2020

    - Seeking Alpha

  4. Upcoming data may highlight biopharma with 364% upside

    8:48 p.m. June 4, 2020

    - Seeking Alpha

  5. 10-Q: CORBUS PHARMACEUTICALS HOLDINGS, INC.

    5:02 p.m. May 11, 2020

    - Edgar Online - (EDG = 10Q, 10K)

  6. Corbus announces open market sale agreement with Jefferies

    10:36 a.m. May 4, 2020

    - Seeking Alpha

  7. RemeGen candidate Fast Track'd for lupus

    11:13 a.m. April 15, 2020

    - Seeking Alpha

  8. RBC sees 21% upside in Danaher in premarket analyst action

    7:23 a.m. March 26, 2020

    - Seeking Alpha

  9. Loading more headlines...

At a Glance

Corbus Pharmaceuticals Holdings, Inc.

500 River Ridge Drive

Second floor

Norwood, Massachusetts 02062

Phone

1 6179630100

Industry

Biotechnology

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2020

Revenue

$36.14M

Net Income

$-71.45M

2019 Sales Growth

649.5%

Employees

141.00

/news/pressrelease/company/us/crbp

Press Releases on CRBP

  1. Most Popular Robinhood Stocks: $CPRX $CRBP $NRZ

    10:26 a.m. Aug. 10, 2020

    - The Market Signal

  2. Loading more headlines...
Link to MarketWatch's Slice.